In this interview at a MetFix Foundations Seminar in Seattle, Bruce Edwards—who served for several years as Chief Operating Officer of CrossFit Inc. —reflects on his long relationship with Greg Glassman, the evolution of the fitness movement, and what drew him to MetFix as an attendee. Edwards describes himself as an average athlete who nonetheless experienced profound improvements in health and strength through training and community, but admits that longstanding struggles with sugar addiction and deteriorating biomarkers persisted despite decades immersed in fitness culture. He explains that MetFix resonated because it connects behavior change, chronic disease, and aging to mitochondrial energy systems, offering the biochemical understanding he believes is essential for both coaches and individuals. In conversation with Emily Kaplan, Edwards points out that loss of metabolic health and mobility—not aging itself—is what ultimately erodes independence and quality of life, drawing on personal family experience. He frames MetFix not as a replacement for movement-based training, but as its nutritional and metabolic foundation: a complementary entry point that empowers people to make informed choices, restore health, and improve the human condition through education, community, and practical application.

MetFix is an education company developing and deploying advanced teachings on metabolic health.

Support the Broken Science Initiative.
Subscribe today →

Leave A Comment

recent posts

    At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.

    The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.

    An abbreviated version of this discussion is available here, for free.

    At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.

    Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.

    The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.

    An abbreviated version of this discussion is available here, for free.

    MetFix and BSI Members can view the full 54-minute video.

  • Metabolic health, medical education, and the case for bringing clinicians and coaches together